Medicare Appeals Rule Expedited By Visudyne Settlement; MCAC To Convene

CMS' Medicare Coverage Advisory Committee will review initial data from QLT, Inc.'s Phase III trial investigating Visudyne (verteporfin) ocular photodynamic therapy in age-related macular degeneration patients with occult lesions